dkNET community events and announcements in October, 2021

Dear dkNET Community,

dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.

dkNET News

• Join dkNET Upcoming Webinars in October: Save the dates! (1) GeneNetwork: Experimental Precision Medicine and Smart FAIR+ Data for Metabolomics and Diabetes Research, presented by Dr. Robert W. Williams, will be held on Friday, October 8, 2021, 11 am-12 pm PT. Register it now! (2) YCharOS - Antibody Characterization Through Open Science, presented by Dr. Carl Laflamme, will be held on Friday, October 22, 2021, 11 am-12 pm PT.

• Recordings and Slides are Now Available for the dkNET Hypothesis Center Live Demo, presented by Dr. Jeffrey Grethe: Recording; Slides.

• New Resources added to dkNET
• Panorama (RRID:SCR_021652)  is an open-source data management system for mass spectrometry data processed with Skyline targeted mass spectrometry environment.

• Lipid Droplet Knowledge Portal (RRID:SCR_021650) is an interactive portal that provides datasets, across a variety of cell types, for LD biology, including transcriptional profiles of induced lipid storage, organellar proteomics, genome-wide screen phenotypes, and ties to human genetics.

• AstraZeneca PheWAS Portal (RRID:SCR_021643) is a repository of gene-phenotype associations for phenotypes derived from electronic health records, questionnaire data, and continuous traits computed on exomes released by UK Biobank.

• NetMHC (RRID:SCR_021651) is a web tool for binding prediction of peptides to MHC class I molecules. The newest version NetMHC- 4.0 is used for prediction of peptide MHC class I binding affinity using gapped sequence alignment that allows insertions and deletions in alignment.

• eQTL Catalogue (RRID:SCR_021700) is a catalog that provides uniformly processed gene expression and splicing QTLs from all available public studies on human. It contains expression and splicing QTLs recomputed from public datasets.

• Open Targets Genetics Portal (RRID:SCR_021701) is a portal that offers features to help discover associations between genes, variants, and traits including Browse and rank gene and variant associations identified by Locus-to-Gene (L2G) scoring pipeline, uncover credible sets for variant and trait associations based on mapping analyses pipeline, and explore and compare studies from UK Biobank, FinnGen, and GWAS Catalog using multi-trait comparison tool eQTL Catalogue.

• Open Targets Platform (RRID:SCR_021702) is a platform for supporting systematic drug–target identification and prioritization. It provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritization for drug discovery based upon underlying evidence.

• HuBMAP Data Portal (RRID:SCR_021703) is a data portal as part of the Human BioMolecular Atlas Program. Data available on HuBMAP Portal is open access data to be used for the research of human biology.

Events in October 2021

Oct. 01, 2021 

dkNET & the(sugar)science D-Challenge Kick-off Meeting

The D-Challenge is a community research challenge designed to increase awareness and use of the rich ecosystem of online tools and data findable through dkNET to develop a compelling hypothesis about the biology, treatment, or sequelae of Type 1 Diabetes. The goal in this challenge is to bring investigators across disciplines to apply their skills and passion to the problem of T1D:  its biology, treatment and sequelae, through the use of a rich interconnected ecosystem of data tools and resources. The winning teams will be awarded up to $20,000 in total cash prizes to further their research. D-Challenge kick-off meeting will be at 9am PDT on October 1, 2021.

More Information: https://info.thesugarscience.org/dknet-21-d-challenge 

Oct. 05, 2021 

Boston NORC Webinar: Conducting Focus Groups with Children

The vast majority of texts and literature on conducting focus groups are geared toward adults as participants. Yet, there is an imperative to conduct qualitative research with children to inform all phases of interventions and programs that include them. This webinar will cover the major issues to consider when conducting focus groups with children ages 6-12, including different strategies to use for different ages and unique challenges to consider. Whether you have experience in conducting groups with adults and would like to adapt your skills, or are completely new to conducting focus groups, you’ll come away with knowledge of the major considerations when working with children.

Webinar streams on October 5 @ 12:00-1:00 pm EST (9am-10am PST)

More Information: https://norccentral.org/event/webiner-conducting-focus-groups-with-children/

Oct. 08, 2021 

dkNET Webinar: GeneNetwork: Experimental Precision Medicine And Smart FAIR+ Data For Metabolomics And Diabetes Research

Abstract

The challenge of precision medicine is to model complex interactions among DNA variants, phenotypes, development, environments, and treatments. The community of researchers using animal models must address the challenge of both genetic and environmental complexity typical of human populations. We have developed large families of mice and rats that can be used as uniquely powerful model for experimental versions of precision medicine. For example, the BXD family of mice segregates for 6 million common DNA variants—a level that exceeds many human populations. Because each member is an isogenic strain, the entire family can be replicated in many environments and offered many treatments. Heritable traits can be mapped with high power and precision. The current BXD phenome is unsurpassed in coverage and include deep omics data and thousands of quantitative traits—including a great deal of data relevant to metabolism, obesity, aging, kidney function, and insulin levels. These new Experimental Precision Medicine resources can be expanded to as many as 20,000 isogenic but non-inbred F1 progeny and be used as a far more effective platform for testing causal modeling and for predictive validation—unique core resources for the fields of prevention and therapeutics.

Presenter: Robert W. Williams, Ph.D. Chair, Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, UT-ORNL Governor's Chair in Computational Genomics

Tune into the webinar on Oct. 8, 2021 at 11am-12pm PDT. 

More Information: https://dknet.org/about/blog/2310

Oct. 14-15, 2021 

NIDDK Webinar "Impaired Hypoglycemia Awareness in T1DM"

Objectives

• Identify obstacles that have hindered progress in the prevention and treatment of IAH in T1D.

• Discuss the limitations of models of IAH and how they can be improved.

• Discuss identification, measurement, and treatment of IAH in patients with T1D.

• Discuss research gaps that, if addressed, could move the field forward to improved prevention and treatment of IAH.

• Foster interactions between clinical and basic scientists with expertise in T1D, metabolism, and neuroscience.

Registration Deadline: October 1, 2021

NIDDK Webinar: October 14-15, 2021

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2021/Impaired-Hypoglycemia-Awareness-T1DM

Oct. 15, 2021 

NORC Webinar: Sustaining Behavior Change Conference: The Greatest Challenge in Promoting Good Health

The Sustaining Behavior Change Conference grows from the belief that limitations in our ability to help people make lasting changes in their health-related behaviors is one of the greatest challenges to the well-being of our population. This conference assembles a group of leading scholars in a range of disciplines, including behavioral sciences, behavioral economics, marketing and neuroscience to share their insights and perspectives on this important issue. Our goal is to spur creative new thinking about how we might study and implement strategies that will foster effective long-term behavior change. 

Day One: October 15, 2021

Day Two: October 22, 2021

More Information: anschutzwellness.com/sbc

Oct. 18-21, 2021 

18th Euro Fed Lipid Congress and Expo (Online Meeting)

Where everything in life goes virtual, we will also go VIRTUAL with the 18th Euro Fed Lipid Congress and Expo to take place 18-21 October 2021 (Online Meeting). We hope this will help you to keep up to date with the latest scientific developments in your field, to network with your peers and exhibitors and to share your research via oral and poster presentations.

More Information: https://veranstaltungen.gdch.de/tms/frontend/index.cfm?l=10713&modus=

Oct. 20, 2021 

LIPID MAPS Webinar: "Lipidomics and Phospholipases"

During the last 40 years, Dr. Gross’ laboratory is known for its work on lipidomics, intracellular phospholipases, mitochondrial function and the roles of membrane molecular dynamics and physical properties in modulating transmembrane protein functions. He has authored over 200 peer-reviewed publications and numerous review articles. Dr. Gross was the principal investigator on a 20-year Program Project Grant on the biochemical mechanisms mediating diabetic cardiomyopathy. These studies identified mitochondrial dysfunction due to activation of phospholipases as important mediators of ischemia and diabetic heart disease.

Presented by: Professor Richard Gross

Tune into this webinar on October 20, 2021 at 5pm BST | 9am PDT | 12pm EDT

More Information: https://www.lipidmaps.org/resources/webinars/15

Oct. 20, 2021 

Registration Deadline: 18th Immunology Diabetes Society Congress

The Immunology of Diabetes Society (IDS) is dedicated to improving our understanding of the pathogenesis and treatment of type 1 diabetes. We invite you to the 18th IDS Congress which will be an in-person meeting in Nashville, TN, USA, on November 1st - 4th, 2021.

More Information: https://www.idsnashville2021.org/ 

Oct. 22, 2021 

dkNET Webinar: YCharOS - Antibody Characterization Through Open Science

Abstract

Many (most!) genes/proteins linked to disease phenotypes remain severely understudied [1]. Distinct open-science initiatives are needed to promote the exploration of currently understudied proteins, from the proper identification of research reagents [2], to the development of a chemical probes for every human protein [1]. We focus on the proper characterization of antibodies to guide researchers in selecting the most specific/selective antibodies for their needed application(s) [3].

Antibodies are among the most commonly used reagents in cell biology. Generally, scientists purchase antibodies from commercial suppliers, and rely on the vendor’s quality control data to make their purchasing decisions. While there are many outstanding commercially-available antibodies, many other antibodies do not perform as advertised - and in the absence of an objective means to compare performance, it is impossible to tell one from the other. This is a widely known problem that plagues tens of thousands of scientists annually [4-6].

There is a scientific solution, enabled by CRISPR/Cas9 technology. By comparing signals from wild-type and isogenic knockout cells, one can readily test the specificity of antibodies. We applied this approach in a pilot study demonstrating that only three of the 16 commercially-available antibodies for C9ORF72, the protein product of a major amyotrophic lateral sclerosis disease locus, specifically recognized the protein. Distressingly, neither antibody had been used in a publication, and the antibody used most frequently in publications, which have been cited thousands of times, did not recognize the protein in any application [7].

We are now applying our antibody characterization pipeline to generate head-to-head comparisons of commercial antibodies for all human proteins. This work is performed in partnership with high-quality manufacturers that provide in-kind reagents (i.e. antibodies and knock-out lines). Finalized antibody characterization reports are progressively uploaded on a free open-science repository (https://zenodo.org/communities/ycharos/). We believe our initiative, Antibody Characterization through Open Science (YCharOS), will contribute to make science more reproducible and help illuminate the dark genome.

Presenter: Carl Laflamme, PhD, Senior Postdoctoral Fellow at the Montreal Neurological Institute (The Neuro, McGill University) in the laboratory of Peter McPherson, distinguished James McGill professor.

Tune in on October 22, 2021 at 11am-12pm PDT.

More Information: https://dknet.org/about/webinar

Oct. 22, 2021 

NORC Webinar: Sustaining Behavior Change Conference: The Greatest Challenge in Promoting Good Health

The Sustaining Behavior Change Conference grows from the belief that limitations in our ability to help people make lasting changes in their health-related behaviors is one of the greatest challenges to the well-being of our population. This conference assembles a group of leading scholars in a range of disciplines, including behavioral sciences, behavioral economics, marketing and neuroscience to share their insights and perspectives on this important issue. Our goal is to spur creative new thinking about how we might study and implement strategies that will foster effective long-term behavior change. 

Day One: October 15, 2021

Day Two: October 22, 2021

More Information: anschutzwellness.com/sbc

Oct. 28-29, 2021 

NMRI South Regional Workshop

More than 700 researchers have participated in NMRI workshops in the past decade, and approximately 100+ are active members. The success of the NMRI, a network that is “owned” by its members and supported by the NIDDK, begins with the dedication of senior investigators who mentor and serve as role models for junior investigators. The participation of active members and the recruitment of new members is a primary reason for the Network’s success in the past and the reason for confidence that it will continue to grow in the future.

Workshop takes place on Oct. 28 - 29, 2021. Register by Oct. 8, 2021

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2021/nmri-south-regional-workshop

Funding Opportunities Information and Deadlines in October 2021

Oct. 01, 2021

The Human BioMolecular Atlas Program (HuBMAP) Funding Opportunity Letter of Intent Due: HuBMAP Integration, Visualization & Engagement (HIVE) Collaboratory (OT2)

The purpose of this Research Opportunity Announcement (ROA) is to solicit applications for the HuBMAP Integration, Visualization & Engagement (HIVE) Collaboratory that will: 1) manage the data generated by the HuBMAP Consortium, 2) coordinate internal and external Consortium activities, 3) develop novel tools for visualizing, searching, and modelling data and 4) build an atlas of tissue maps. The HIVE will be composed of projects funded in three component areas all of which are expected to work closely together to act as the unified backbone for the HuBMAP Project. The HIVE is expected to work closely with the other funded projects as part of the HuBMAP Consortium to catalyze development of a framework for mapping the human body and exemplarily maps with high spatial resolution. *Invitation to submit full proposal will be sent. Application Deadline: December 3, 2021

More Information: https://commonfund.nih.gov/sites/default/files/HuBMAP-HIVE-OTA-21-012-v2-508.pdf

Oct. 03, 2021 

NIDDK Funding Opportunity Letter of Intent Due: Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinical trials and patient care. This initiative will support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative will leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples. The goal of this initiative is to deliver candidate biomarkers that are ready for definitive analytical and clinical validation studies through the Diabetic Foot Consortium. 

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-001.html

Oct. 03, 2021 

NIDDK Funding Opportunity Letter of Intent Due: Characterization of Islet-derived Extracellular Vesicles for Improved Detection, Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed)

This initiative will support the development of tools and experimental platforms for the purification and characterization of Extracellular Vesicles (EV) originating from the human pancreatic islet and its broader tissue environment in healthy individuals, and individuals with T1D or at-risk of developing the disease. It will also support the exploration of the contribution of pancreatic EV biology to islet function, dysfunction and T1D disease initiation; the development of EV-based diagnostic tools for disease monitoring and classification; and the use of pancreatic EV biology to identify novel therapeutic targets. Application Deadline: November 3, 2021

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-016.html

Oct. 05, 2021 

NIH Funding Opportunity Application Due: New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)

Description:This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.

More Information: https://grants.nih.gov/grants/guide/pa-files/pas-21-150.html 

Oct. 05, 2021 

NIH Funding Opportunity Application Due: Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)

This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.

More Information: https://grants.nih.gov/grants/guide/pa-files/pa-21-232.html

Oct. 05, 2021 

NIDDK Funding Opportunity First Available Due: Notice of Special Interest: Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders

Gastrointestinal (GI) complications in children and adults with neurodevelopmental disorders have drawn attention to gaps in understanding their causes and treatment. GI dysfunction is particularly common in individuals with neurodevelopmental disorders such as autism, Fragile X syndrome, and Rett syndrome, as well as chromosomal disorders such as Down syndrome. GI disorders in these conditions can include gut malformations present at birth (such as pyloric stenosis or Hirschsprung disease) but also functional issues such as feeding problems, gastro-esophageal reflux disease (GERD), cyclic vomiting, delayed gastric emptying, diarrhea, bloating, celiac disease, irritable bowel symptoms, and constipation leading to encopresis, incontinence, and stool impaction. These GI issues may be associated with severe nutritional deficiencies, weight loss, and failure to thrive. GI symptoms are reported in between 23-70% of individuals with autism, a rate ~ 8 times higher than in the general population, with similar rates in individuals with other less common forms of intellectual and developmental disabilities (IDD) (Holingue et al., Autism Res 2018:11:24-36). Unfortunately, mechanisms to accurately diagnose GI conditions in this population are limited, and tailored treatments to address them are almost nonexistent, particularly since clinical trials for IDD populations are rare. Submission Deadline: begins October 5, 2021, through July 16, 2024.

More Information: https://grants.nih.gov/grants/guide/notice-files/not-dk-21-024.html

Oct. 09, 2021 

NIDDK Funding Opportunity Letter of Intent Due: NIDDK Research Education Program Utilizing Stimulating Peripheral Activity to Relieve Conditions (SPARC) - Generated Resources (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences; Courses for Skills Development. This Funding Opportunity Announcement (FOA) invites applications to establish research programs for qualified graduate students, post-doctoral fellows, medicalresidents, biomedical engineers, and clinical fellows to engage in neuroscience research experiences relevant to the mission of NIDDK and its partnership with the Common Fund program, Stimulating Peripheral Activity to Relieve Conditions (SPARC). The intent is to leverage this partnership to provide resources for short-term research experiences that would necessarily use SPARC-generated resources (datasets/maps/models) as the foundation for the research experience in conjunction with educational activities that may be combined with hands-on computational or ‘wet lab’ projects. The goal is that the research experiences will be impactful and ideally develop new skills and produce new knowledge that could sustain future NIDDK-funded research careers. 

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-20-020.html

Oct. 15, 2021 

NIH Funding Opportunity Application Due: Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 – Clinical Trial Optional)

This funding opportunity is intended to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease among individuals with Type 1 Diabetes Mellitus (T1DM) and advances the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. Letter of Intent due 30 days prior to the application due date.

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-21-014.html

Oct. 15, 2021 

NIH Funding Opportunity Application Due: HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress. 

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-21-010.html

Oct. 15, 2021 

NIH Office of Portfolio Analysis (OPA) Request for Information (RFI) Submission Deadline:User Experience with Scientific Data Sources and Tools

The Office of Portfolio Analysis (OPA) was established in 2011 and is part of the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) within the Office of the NIH Director (OD). OPA supports the NIH mission by expanding its analytic capabilities through development and dissemination of new methods, data sources, computational tools, and best practices for data-driven decision making. The following website provides an overview of previous and current OPA activities: https://dpcpsi.nih.gov/opa

More Information: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-182.html

Oct. 16, 2021 

NIH Funding Opportunity Application Due: Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)

This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs’ (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.

More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-21-167.html

Oct. 17, 2021 

NIDDK Funding Opportunity Letter of Intent Due: Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental mechanisms underlying HIV-associated comorbidities, coinfections, and complications relevant to the mission of the NIDDK and advance progress toward alleviating them. Application Deadline: November 17, 2021

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-20-022.html

Oct. 18, 2021 

NIDDK Funding Opportunity Letter of Intent Due: Pediatric Centers of Excellence in Nephrology (P50 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications for the Pediatric Centers of Excellence in Nephrology (PCEN) to support basic, translational and clinical research in pediatric kidney disease. The goals of this program are: 1. to attract new scientific expertise to the study of human pediatric renal physiology, kidney development, and pediatric kidney disorders; 2. to encourage multidisciplinary research in these areas; and 3. to develop the pediatric nephrology research community through a national research symposium, broad sharing of research resources, and a national Pilot and Feasibility grant program. These efforts are expected to lead to innovative approaches to study kidney disease in children and the eventual submission of substantial, competitive, investigator–initiated research applications. The PCEN will complement the O’Brien Kidney and Urological Research Centers and are expected to leverage existing institutional resources which may include Clinical Translational Science Awards, Institutional Network Awards for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1), and other NIDDK-Division of Kidney, Urologic and Hematologic Diseases (KUH)-funded consortia. Application Deadline: November 18, 2021

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-024.html

Oct. 19, 2021 

NIH Funding Opportunity Letter of Intent Due: Tissue Mapping Centers for the Human BioMolecular Atlas Program (U54 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) that will generate a high-resolution, high-content, multiscale atlas of a non-diseased human organ. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration, analysis and interpretation. Centers will also be expected to work closely with the other funded projects as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body in 3D with high resolution. Application Deadline: November 19, 2021

More Information:https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-026.html

Oct. 20, 2021 

NIDDK Funding Opportunity Application Due: Standardization of C-Peptide and HbA1C Measurements Program (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites applications for a Central Primary Reference Laboratory (CPRL) to provide support for the harmonization and standardization of laboratory measurements critical for clinical research in type 1 diabetes. The CPRL will provide administrative functions to coordinate harmonization efforts among clinical laboratories and commercial suppliers of reagents and methods, and will provide measurements of reference values for C-peptide and HbA1c measurements.

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-007.html

Oct. 20, 2021 

NIH Funding Opportunity Application Due: Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)

The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledgebase of microbial metabolites and associated functions that will be provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (Clinical Trial Not Allowed).

More Information: https://grants.nih.gov/grants/guide/pa-files/par-21-253.html

Oct. 20, 2021 

NIDDK Funding Opportunity Application Due: Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (U24 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites U24 cooperative agreement applications for a Knowledge Management Center (KMC) to support the grantees funded by a companion announcement PAR-21-253: Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed), engaged in identifying and characterizing microbial metabolites for building a knowledgebase. PAR-21-253 invites applications for identifying and characterizing microbial metabolites that will be used by this KMC to create a knowledgebase on microbial metabolites that is accessible to the research community.

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-014.html

Oct. 20, 2021 

NIDDK Funding Opportunity Application Deadline: Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell interventions using novel cell sources, immune-modulatory strategies, biomaterials and devices for T1D treatment.

More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-006.html

Oct. 20, 2021 

NIDDK Funding Opportunity Application Due: Nutrition Obesity Research Centers (P30 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and an Enrichment program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness and multidisciplinary nature of research in nutrition and obesity. 

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-015.html

Oct. 25, 2021 

Kidney Precision Medicine Project Funding Opportunity Application Due: Biomarker Measurements

This solicitation will provide KPMP opportunity pool funds to use stored samples from KPMP participants

to measure biomarkers that can be utilized to enrich normal and pathological phenotyping of KPMP

participants and predict clinical course of renal disease. Applications must propose a strong justification

for the use of the proposed biomarkers based on the bullets below and will use funds to measure their

proposed biomarkers in the provided KPMP biosamples.

Application Deadline: October 25, 2021 at 5pm EST

Scroll to "KPMP Biomarker Measurements" and select "View the RFA"

More Information: https://www.kpmp.org/opportunity-pool

Oct. 25, 2021 

AMP-CMD Opportunity Pool Funding Funding Opportunity Proposal Deadline

The Accelerating Medicines Partnership in Common Metabolic Diseases (AMP-CMD) is a public-private partnership to identify drivers of common metabolic diseases, including nonalcoholic steatohepatitis, chronic kidney disease, obesity, atherosclerotic cardiovascular disease and heart failure, type 2 diabetes/prediabetes, autoimmune diabetes, and inflammation. AMP-CMD supports the generation and analysis of genetic association results, epigenomic annotations, and functional studies, and the representation of these results in the open-access Common Metabolic Diseases Knowledge Portal. In keeping with the model of multi-institution collaboration on which AMP-CMD is based, we are opening the Funding Opportunity described below to researchers outside of the AMP-CMD consortium.

The current 5-year AMP-CMD award includes funding for an annual opportunity pool (OP) to support projects to address research directions that would further consortium goals but are not currently ongoing in the consortium. The OP comprises $500,000 total cost for each of the 5 years of the AMP-CMD award. 

More Information: http://kp4cd.org/amp-cmd-foa2021

Oct. 26, 2021 

NIDDK Funding Opportunity Application Due: NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)

The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability.

More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-19-319.html